Feature | March 24, 2014

New Treatment for Atrial Fibrillation Reduces Stroke Risk

Lariat device seals the left atrial appendage

atrial fibrillation, LARIAT
March 24, 2014 – Doctors at the Stony Brook Heart Institute Electrophysiology Lab are using a new nonsurgical technique called the Lariat Suture Delivery Device to treat patients with atrial fibrillation (AF) who cannot tolerate blood-thinning medication.
 
AF is the most common heart rhythm disorder that causes the upper chambers of the heart to beat fast and erratically. An estimated 2.7 million Americans are living with the disorder, and if uncontrolled, it can have serious consequences, including stroke and early death. Currently, the condition accounts for more than 20 percent of stroke-related deaths.
 
Patients are normally given blood thinners such as warfarin and other anticoagulants to manage their condition by preventing blood clots. However, patients must rigorously manage the level of the drugs in their blood. For most patients, these blood thinners are very effective in reducing the risk of stroke, but there is a potential for bleeding, which in some cases can be serious. For those individuals who cannot tolerate blood thinners due to prior bleeding or who are at a high risk for bleeding, the Lariat procedure can safely reduce the risk of stroke without any further bleeding risk.
 
The Lariat procedure is a nonsurgical, minimally-invasive technique that uses sutures to tie off the left atrial appendage (LAA) of the heart. This area of the heart is the primary source of blood clots leading to stroke in patients with atrial fibrillation.
 
With the patient under general anesthesia, physicians guide two catheters into the patient’s heart to seal the LAA with a pre-tied suture loop — similar to a lasso — with the Lariat device. Rather than a surgical procedure, the technique uses a needle to introduce catheters into the heart.
 
“In the past there weren’t any alternatives that we could really offer these types of patients,” said Roger Fan, M.D., associate professor, department of medicine, director of arrhythmia consult service. “The Lariat is a great alternative to the possibility of a lifetime of blood thinners, which can have some serious side effects like GI bleeds, as well as an alternative to invasive open-heart surgery.” 
 
On Dec. 3, 2013, Fan and his team at the Stony Brook Heart Institute completed their first Lariat procedure without having to spread the ribcage or cut through bone to reach the heart.
 
For more information, visit www.heart.stonybrookmedicine.edu

Related Content

Feature | Atrial Fibrillation| July 20, 2015
A new study proves race and gender-related disparities exist in care for patients who have recently been diagnosed with...
sentraheart lariet, LAA occlusion, FDA safety alert
Feature | Left Atrial Appendage (LAA) Occluders| July 13, 2015
The U.S. Food and Drug Administration (FDA) is alerting healthcare providers and patients of reports of patient deaths...
Medtronic, CardioInsight, acquisition, ECVUE, cardiac mapping system

Image courtesy of CardioInsight Technologies Inc.

Feature | EP Mapping and Imaging Systems| July 01, 2015
Medtronic has acquired CardioInsight Technologies Inc., a Cleveland-based medical device company that has developed a...
SentreHeart, Lariat Suture Delivery Device, FDA, AMAZE Trial, AFib, LAA
News | Left Atrial Appendage (LAA) Occluders| July 01, 2015
SentreHeart Inc. announced that it has received approval for an Investigational Device Exemption (IDE) from the U.S....
ACC, HRS, SCAI, left atrial appendage occlusion, recommendations
Feature | Left Atrial Appendage (LAA) Occluders| June 30, 2015
The American College of Cardiology (ACC), Heart Rhythm Society (HRS) and Society for Cardiovascular Angiography and...
Videos | Structural Heart| June 26, 2015
Interview with Steve Goldstein, M.D., director, noninvasive lab, Medstar Washington Heart Institute, Washington, D.C.
Videos | Cardiovascular Ultrasound| June 17, 2015
Role of Interventional Echcardiography in Transcatheter Structural Heart Procedures — Rebecca Hahn, M.D., Columbia Un
Videos | Structural Heart| June 17, 2015
Interview with Ted Feldman, M.D., FACC, MSCAI, FESC, cardiac cath lab director, Evanston Hospital, North Shore Health
Aspire, thrombectomy, C. Dorn Smith, aspirators, clot, cold leg, removal

Clot in femoral artery caused by atrial fibrillation

News | Thrombectomy Devices| June 11, 2015
C. Dorn Smith, M.D., vascular surgeon in Kingstree, South Carolina, was successful in using a new device to remove...
rivaroxaban, Xarelto, VENTURE-AF, VKA, atrial fibrillation, Heart Rhythm 2015
News | May 21, 2015
Janssen Pharmaceuticals Inc. and its development partner Bayer HealthCare announced results from the VENTURE-AF trial....
Overlay Init